PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE
100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:
Scientific evidence for clinical utility.
By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrintยฎ and BluePrintยฎ test suite.
Evidence
Molecular Subtyping Improves Diagnostic Stratification of Patients with Primary Breast Cancer into Prognostically-Defined Risk Groups
PUBLICATION: Breast Cancer Res Treat (2015) 154: 81. https://doi.org/10.1007/s10549-015-3587-9. AUTHORS: Katharine Yao, Robert Goldschmidt, Mary TurkJelle Wesseling, Lisette Stork-Sloots, Femke de Snoo, Massimo Cristofanilli SUMMARY: Retrospective, observational study comparing MP+BP subtyping with long-term outcomes: MammaPrint low-risk patients had a 10-year DMFS of 96 % (95 %CI 92.8โ99.4), while MammaPrint high-risk Read More
Application of a 70-Gene Expression Profile to Japanese Breast Cancer Patients
PUBLICATION: Breast Care 2015;10:118-122 https://doi.org/10.1159/000376562. AUTHORS: Shimizu H., Horimoto Y., Arakawa A., Sonoue H., Kurata M., Kosaka T., Nakai K., Himuro T., Tokuda E., Takahashi Y., Taira F., Ito M., Abe I., Senuma K., Stork-Sloots L., de Snoo F., Saito M. SUMMARY: Of 38 cases judged to be at intermediate Read More
Gene Expression Profiling to Predict the Risk of Locoregional Recurrence in Breast Cancer: A Pooled Analysis
PUBLICATION: Breast Cancer Res Treat (2014) 148: 599. https://doi.org/10.1007/s10549-014-3188-z. AUTHORS: C.A. Drukker, S.G. Elias, M.V. Nijenhuis, J. Wesseling, H. Bartelink, P. Elkhuizen, B. Fowble, P.W. Whitworth, R.R. Patel, F.A. de Snoo, L.J. van โt Veer, P.D. Beitsch, E.J. Th. Rutgers SUMMARY: After a median follow-up of 8.96 years with 87 Read More
Genomic Profile of Breast Cancer: Cost-Effectiveness Analysis from the Spanish National Healthcare System Perspective
PUBLICATION: Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):889-99. doi: 10.1586/14737167.2014.957185. Epub 2014 Sep 12. AUTHORS: Seguรญ M.ร., Crespo C., Cortรฉs J., Lluch A., Brosa M., Becerra V., Chiavenna S.M., Gracia A. SUMMARY: A 70-gene signature showed a life expectancy of 23.55 years at lifetime. Life expectancy was lower for 21-gene Read More
Molecular Subtyping Predicts Pathologic Tumor Response in Early-Stage Breast Cancer Treated with Neoadjuvant Docetaxel Plus Capecitabine with or without Trastuzumab Chemotherapy
PUBLICATION: Med Oncol. (2014) 31: 163. https://doi.org/10.1007/s12032-014-0163-9. AUTHORS: Soley Bayraktar, Melanie Royce, Lisette Stork-Sloots, Femke de Snoo, Stefan Glรผck SUMMARY: The overall pCR plus npCR rate was 25 % (30/122). Stratified by BluePrint/MammaPrint, patients of HER2 type had the best response (59 %), while luminal A (7 %) and B Read More
The Multigene Signature MammaPrint Impacts on Multidisciplinary Team Decisions in ER+, HER2โ Early Breast Cancer
PUBLICATION: British Journal of Cancer, volume 111, pages 837โ842 (26 August 2014). AUTHORS: R. Exner, Z. Bago-Horvath, R. Bartsch, M. Mittlboeck, V.P. Retรจl, F. Fitzal, M. Rudas, C. Singer, G. Pfeiler, M. Gnant, R. Jakesz, P. Dubsky SUMMARY: According to MammaPrint (MP), 76% were low risk. In over a third Read More
Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)
PUBLICATION: Annals of Surgical Oncology; October 2014, Volume 21, Issue 10; pp 3261โ3267. AUTHORS: Pat Whitworth, MD; Lisette Stork-Sloots, MSc; Femke A. de Snoo, MD, PhD; Paul Richards, MD; Michael Rotkis, MD; Jennifer Beatty, DO; Angela Mislowsky, MD; James V. Pellicane, MD; Bichlien Nguyen, MD; Laura Lee, MD; Charles Nash, Read More
